EU study to help understand if Intratumoral CD8+ T lymphocytes can predict outcomes in patients with previously untreated stages IIIb to IV melanoma

Amgen has announced the initiation of a clinical trial, NCT02366195, to determine whether baseline CD8+ T lymphocytes density is a biomarker of response to talimogene laherparepvec, an...